– Clúster Médico lamenta que, sin fundamento y por intereses...Leer más
Patients with mild to moderate COVID-19 who were treated for 5 days with VV116, an investigational oral antiviral drug that is active against SARS-CoV-2, recovered as quickly from infection as did those treated with nirmatrelvir-ritonavir (Paxlovid), according to the results of a randomized noninferiority trial published in the New England Journal of Medicine.
The median time for symptoms to resolve was 4 days for those treated with VV116 and 5 days for those treated with nirmatrelvir-ritonavir, based on the results from participants in Shanghai, China.
The time to sustained resolution of symptoms and to the first negative SARS-CoV-2 test result were also similar for the 384 participants treated with VV116 and the 387 treated with nirmatrelvir-ritonavir. Participants treated with VV116 also experienced fewer adverse effects.